A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial
ConclusionsThis novel peptide vaccination therapy was safe for patients with metastatic gastrointestinal cancers.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Gastroenterology | Immunotherapy | Study | Toxicology | Vaccines